Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...
Hosted on MSN16h
GLP-1 Trends by CivicScience: GLP-1 Users Foresee Long-Term Use, Spending More on Clothing and Groceries, Plus MoreThis is just a tiny glimpse of the data available to CivicScience clients. Discover more data. CivicScience has data on over ...
CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.
Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...
Snack foods and sweet treats have seen a decline in purchases, as people reach for more nutrient-dense options.
A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...
Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...
They're known to aid in blood sugar control and, now, weight loss — but, according to a sweeping new study, the popular GLP-1 ...
Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...
Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...
Companies such as Teladoc and Omada Health have embraced GLP-1s while dangling the prospect of lowered costs to their ...
A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback